On final dash to the clinic, ArsenalBio hauls in $220M for ‘modular’ cell therapy approach

If ArsenalBio does it right, its first CAR-T candidate — a potential treatment for ovarian cancer — will be in the clinic later this year.

And a group of deep-pocketed investors are betting $220 million that it can.

South San Francisco-based ArsenalBio launched out of the gate in late...

Click to view original post